+91-8668442535

Human Rabies Treatment Market By Product Type (Top 3 Countries, Cell Culture Vaccines, Rabies Immunoglobulin, Nerve Tissue Vaccines), By Treatment Type (Top 3 Countries, Pre-Exposure Immunization, Post-Exposure Prophylaxis) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Rabies is a fatal neurological disease, usually spread to humans through the bite of a rabid animal, and it is a persistent global problem. Factors such as growing treatment awareness and rising initiatives of government organizations in the prevention of rabies are primarily driving the growth of the human rabies treatment market globally.

The report titled "Human Rabies Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall human rabies treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on product type, treatment type, and different geographical regions. Geographically,

The global human rabies treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global human rabies treatment market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global human rabies treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global human rabies treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global human rabies treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on product type, the global human rabies treatment market is segmented as follows:

  • Vaccines from Cell Culture
  • Rabies Immunoglobulin
  • Nerve tissue vaccines
  • Other

Rabies is a life-threatening viral disease that attacks the nervous system. It is usually spread to humans via the saliva of infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. The human rabies treatment market is categorized on the basis of product types, such as cell culture vaccines, rabies immunoglobulin, nerve tissue vaccines, and others. It is estimated that cell culture vaccines will show significant market growth during the forecast period due to their safety, high immunogenicity, fewer adverse effects, and negligible allergic reactions compared to other types of human rabies treatment. Human diploid cell strain vaccine (HDCV) was the first cell culture vaccine, but to offset its higher cost, international pharmaceutical companies make purified chicken embryo cell vaccine (PCECV) and purified Vero cell culture rabies vaccine (PVRV) available worldwide.

Based on treatment type, the global human rabies treatment market is segmented as follows:

  • Pre-exposure Immunization
  • Post-exposure Prophylaxis

Rabies is a life-threatening illness spread via the saliva of infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Based on treatment type, the global rabies treatment market is segmented into pre-exposure immunization and post-exposure prophylaxis. It is estimated that pre-exposure immunization will show market growth during the forecast period. Pre-exposure immunization is recommended for laboratory workers handling rabies and rabies-related viruses, people whose activities might bring them into direct contact with animals, and travelers to rabies-affected remote areas. According to research, the demand for post-exposure prophylaxis is increasing in developing countries because it is the only safe and effective treatment available on the market to prevent exposed people from contracting rabies. Post-exposure prophylaxis preferably involves the management of an animal bite wound, passive immunization, and active immunization. The World Health Organization (WHO) reports that the average cost of rabies post-exposure prophylaxis (PEP) in Africa is US$ 40 and US$ 49 in Asia. Every year, more than 15 million people worldwide receive a post-bite vaccination.

For the purpose of this study, the global human rabies treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

According to the World Health Organization (WHO), human rabies is present in 150 countries and territories and on all continents except Antarctica, and more than 10,000 people die each year from rabies. Globally, it is estimated that human mortality is highest in Asia, closely followed by Africa. According to the Centers for Disease Control and Prevention (CDC), human rabies is rare in the United States, with 1–3 cases reported annually. It has been studied that demand for pre-exposure immunization is highest in North America, and the United States is the major regional market in North America. It is expected that Asia Pacific will have the highest market growth during the forecast period due to increased initiatives by government agencies and private organizations for rabies prevention; it is also expected that populous countries, growing healthcare awareness, and developing economic conditions will aid in the growth of the human rabies treatment market. 

Frequently Asked Questions:

The market for Human Rabies Treatment is expected to reach US$ 4.32 Bn in 2025.

The Human Rabies Treatment market is expected to see significant CAGR growth over the coming years,at 5.3%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Bio Med Pvt. Ltd.,Biological E Ltd.,Cadila Healthcare,CSC Pharmaceuticals International,GlaxoSmithKline GmbH are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58719
Report Format:   PDF
Pages:   120
Rating:    4.8 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support